| Released | Contributor | Author | Title | Pages | Price |
| 28-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| Angiotech Pharmaceuticals | 5 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | ANGIOTECH PHARMACEUTICALS INC (ANPI=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | ANGIOTECH PHARMACEUTICALS INC (ANPI=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for BIOTECHNOLOGY | 18 |
$49 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: ANGIOTECH PHARM -- ANPI | 1 |
$4 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Health Serv & Equipment Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 21-Nov-2009 | TheStreet.com Ratings |
N/A
| TheStreet.com Ratings Stock Report For: ANGIOTECH PHARMACEUTICALS | 5 |
$25 |
| 19-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ACCL , ANPI , PRX , PBH , TAROF , TGX , VVUS -- DRUGS | 3 |
$4 |
| 14-Nov-2009 | TheStreet.com Ratings |
N/A
| TheStreet.com Ratings Stock Report For: ANGIOTECH PHARMACEUTICALS | 5 |
$25 |
1.48% Nasdaq 
Research Reports
